Ligand Pharmaceuticals
LGND
270 hedge funds and large institutions have $2.52B invested in Ligand Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 99 increasing their positions, 100 reducing their positions, and 26 closing their positions.
54% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 26
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
4% more funds holding
Funds holding: 260 → 270 (+10)
0.15% less ownership
Funds ownership: 119.56% → 119.41% (-0.15%)
0% less capital invested
Capital invested by funds: $2.53B → $2.52B (-$12.4M)
1% less repeat investments, than reductions
Existing positions increased: 99 | Existing positions reduced: 100
34% less call options, than puts
Call options by funds: $31.8M | Put options by funds: $47.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$52.6M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$29.2M |
| 3 |
William Blair Investment Management
Chicago,
Illinois
|
+$23.4M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$19M |
| 5 |
CCMLC
Cardinal Capital Management LLC (Connecticut)
Greenwich,
Connecticut
|
+$9.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$47.9M |
| 2 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
-$14.5M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$14.3M |
| 4 |
CM
Castleark Management
Chicago,
Illinois
|
-$13.1M |
| 5 |
TA
Teachers Advisors
New York
|
-$11.6M |
LGND Hedge Fund Activity: Q4 2016 in Review
270 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q4 2016, worth a combined $2.52B — down 0.49% from $2.53B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new LGND positions and 26 closed out — a net gain of 14 holders — while 99 added to existing stakes and 100 trimmed.
The largest buyer was Scopia Capital Management, opening a new position worth an estimated $52.6M. The largest seller was Fidelity Investments, cutting an estimated $47.9M.
- 270 institutional investors held Ligand Pharmaceuticals (LGND) as of Q4 2016, up from 260 in Q3 2016.
- Funds reported $2.52B of Ligand Pharmaceuticals stock for Q4 2016, down 0.49% quarter-over-quarter.
- 40 funds opened new Ligand Pharmaceuticals positions in Q4 2016 and 26 closed out, a net change of +14 holders.
- The largest Ligand Pharmaceuticals buyer in Q4 2016 was Scopia Capital Management, an estimated $52.6M added.
- The largest Ligand Pharmaceuticals seller in Q4 2016 was Fidelity Investments, an estimated $47.9M sold.
Based on aggregated 13F filings for Q4 2016.